Summary
Global Markets Direct’s, ‘Obsessive-Compulsive Disorder - Pipeline Review, H2 2016’, provides an overview of the Obsessive-Compulsive Disorder pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Obsessive-Compulsive Disorder, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Obsessive-Compulsive Disorder and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Obsessive-Compulsive Disorder
- The report reviews pipeline therapeutics for Obsessive-Compulsive Disorder by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Obsessive-Compulsive Disorder therapeutics and enlists all their major and minor projects
- The report assesses Obsessive-Compulsive Disorder therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Obsessive-Compulsive Disorder
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Obsessive-Compulsive Disorder
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Obsessive-Compulsive Disorder pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
AbbVie Inc.
Addex Therapeutics Ltd
Amorsa Therapeutics Inc.
C4X Discovery Holdings PLC
Novartis AG
Omeros Corporation
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Obsessive-Compulsive Disorder Overview 6
Therapeutics Development 7
Pipeline Products for Obsessive-Compulsive Disorder - Overview 7
Obsessive-Compulsive Disorder - Therapeutics under Development by Companies 8
Obsessive-Compulsive Disorder - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Early Stage Products 11
Obsessive-Compulsive Disorder - Products under Development by Companies 12
Obsessive-Compulsive Disorder - Companies Involved in Therapeutics Development 13
AbbVie Inc. 13
Addex Therapeutics Ltd 14
Amorsa Therapeutics Inc. 15
C4X Discovery Holdings PLC 16
Novartis AG 17
Omeros Corporation 18
Obsessive-Compulsive Disorder - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 25
Drug Profiles 26
18-MC - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
ADX-71743 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
ADX-88178 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
fluvoxamine maleate - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
mavoglurant - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
OMS-527 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Small Molecules for Autism Spectrum Disorders and Obsessive Compulsive Disorders - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Small Molecules to Antagonize Orexin-1 Receptor for CNS Disorders - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Small Molecules to Target NMDA Receptor for Obsessive-Compulsive Disorder - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Obsessive-Compulsive Disorder - Dormant Projects 38
Obsessive-Compulsive Disorder - Discontinued Products 39
Obsessive-Compulsive Disorder - Product Development Milestones 40
Featured News & Press Releases 40
Mar 19, 2013: Omeros Elucidates Mechanism Of PDE7 Inhibitors In Addiction 40
Aug 02, 2007: Jazz Pharmaceuticals, Inc. Announces Submission of Complete Responses to FDA Approvable Letters for Luvox 40
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 41
Disclaimer 42
List of Tables
Number of Products under Development for Obsessive-Compulsive Disorder, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Late Stage Development, H2 2016 9
Comparative Analysis by Clinical Stage Development, H2 2016 10
Comparative Analysis by Early Stage Development, H2 2016 11
Products under Development by Companies, H2 2016 12
Obsessive-Compulsive Disorder - Pipeline by AbbVie Inc., H2 2016 13
Obsessive-Compulsive Disorder - Pipeline by Addex Therapeutics Ltd, H2 2016 14
Obsessive-Compulsive Disorder - Pipeline by Amorsa Therapeutics Inc., H2 2016 15
Obsessive-Compulsive Disorder - Pipeline by C4X Discovery Holdings PLC, H2 2016 16
Obsessive-Compulsive Disorder - Pipeline by Novartis AG, H2 2016 17
Obsessive-Compulsive Disorder - Pipeline by Omeros Corporation, H2 2016 18
Assessment by Monotherapy Products, H2 2016 19
Number of Products by Stage and Target, H2 2016 21
Number of Products by Stage and Mechanism of Action, H2 2016 23
Number of Products by Stage and Route of Administration, H2 2016 24
Number of Products by Stage and Molecule Type, H2 2016 25
Obsessive-Compulsive Disorder - Dormant Projects, H2 2016 38
Obsessive-Compulsive Disorder - Discontinued Products, H2 2016 39
List of Figures
Number of Products under Development for Obsessive-Compulsive Disorder, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Early Stage Products, H2 2016 11
Assessment by Monotherapy Products, H2 2016 19
Number of Products by Targets, H2 2016 20
Number of Products by Stage and Targets, H2 2016 20
Number of Products by Mechanism of Actions, H2 2016 22
Number of Products by Stage and Mechanism of Actions, H2 2016 22
Number of Products by Stage and Routes of Administration, H2 2016 24
Number of Products by Stage and Molecule Types, H2 2016 25
